Connect with us

Technology

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Published

on

LAUSANNE, Switzerland, Feb. 3, 2025 /PRNewswire/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 26,800 of the Company’s common shares to three new employees on February 3, 2025 (each, a “Grant”).

The Grants were offered as material inducement to the employees’ employment. The grants were approved by the Compensation Committee of the Company’s Board of Directors pursuant to the Company’s Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08.

The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on LinkedIn.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “would”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “future”, “continue”, or “appear” or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the expected cash runway into mid-2026 the Company’s ability to grow ZYNLONTA® revenue in the United States; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company’s or its partners’ research and development projects or clinical trials including LOTIS 5 and 7, ADCT 602 as well as early research in certain solid tumors with different targets, linkers and payloads; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company’s products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company’s indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company’s activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the “Risk Factors” section of the Company’s Annual Report on Form 10-K and in the Company’s other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

CONTACTS:

Investors
Marcy Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450

Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040

View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-302366710.html

SOURCE ADC Therapeutics SA

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

SolRiver Announces the Start of Construction on its Longleaf Solar Project in Davie County, North Carolina

Published

on

By

The project marks SolRiver’s 12th project in the Carolinas

ADVANCE, N.C., March 14, 2025 /PRNewswire/ — SolRiver Capital, a Denver-based renewable energy investment firm, announced the start of onsite construction at its 7 MW Longleaf Solar Project in Davie County, North Carolina. SolRiver acquired the project as a development asset, finished the remaining development work, and brought the project to Notice to Proceed (NTP). The project will be owned and operated as part of the company’s larger Carolinas portfolio.

Riley Sullivan, Executive Vice President at SolRiver Capital, commented, “When we purchased the Longleaf project, it wasn’t quite ready to build yet. Fortunately, we have a good playbook for wrapping up development and getting projects built.”

Once finished, SolRiver will have brought a dozen solar projects online in the Carolinas, totaling approximately 100 MW of generating capacity. Longleaf Solar is expected to become operational in Q2 2025. The company is also building the Williams project, a 6 MW installation expected to come online around the same time as Longleaf.

Brandon Conard, Managing Partner at SolRiver Capital, stated, “We’ve been active in this market since 2019 and are happy to add more assets to the mix in North and South Carolina.”

The project is utilizing safe-harbor panels purchased and delivered in 2023. Eligible for safe harbor, these panels were stored in a North Carolina warehouse and have been deployed on this project as well as several other projects built over the past two years. Panel deliveries were recently completed at the Longleaf site. “This approach helped us stay ahead in a rapidly evolving market.” added Brandon Conard.

About SolRiver Capital:
SolRiver Capital (https://solrivercapital.com/) is a leading renewable energy investment firm dedicated to financing the development, construction, and acquisition of projects across the U.S. Founded in 2016, SolRiver currently manages over 1.5 GW of projects across multiple markets and technologies. With a focus on forging strong partnerships and delivering innovative solutions, SolRiver Capital invests in projects that advance sustainability and foster economic growth.

View original content to download multimedia:https://www.prnewswire.com/news-releases/solriver-announces-the-start-of-construction-on-its-longleaf-solar-project-in-davie-county-north-carolina-302402155.html

SOURCE SolRiver Capital

Continue Reading

Technology

Versus Sports Simulator Expands Coverage to Include Women’s D1 College Basketball and Men’s D2/D3 College Basketball

Published

on

By

Versus Sports Simulator expands its coverage to include Women’s NCAA D1 College Basketball and Men’s NCAA D2/D3 College Basketball, offering fans comprehensive rankings and data insights across additional divisions. This expansion further solidifies the platform’s position as a leading resource for sports analysis.

RICHMOND, Va., March 14, 2025 /PRNewswire-PRWeb/ — Versus Sports Simulator, a trusted resource for sports rankings and data analysis for over 15 years, is proud to announce the expansion of its college basketball coverage. In addition to its long-standing coverage of Men’s NCAA Division I College Basketball, the platform now offers comprehensive rankings and data insights for Women’s D1 College Basketball as well as Men’s D2 and D3 College Basketball.

Expanding our coverage to include additional college basketball divisions felt like the natural next step, and we are extremely excited to contribute our unique data insights into this space.

Founder Steve Pugh shared his excitement about the expansion: “For 15 years, fans of the game have enjoyed our College Basketball rankings and insights, and the feedback has been overwhelmingly positive. Our product has earned respect and appreciation from sports enthusiasts nationwide. Expanding our coverage to include additional college basketball divisions felt like the natural next step, and we are extremely excited to contribute our unique data insights into this space.”

The Versus Sports Simulator platform empowers sports fans, analysts, and bracket enthusiasts with proprietary mathematical models that generate precise predictions and valuable insights. Users can explore comprehensive team rankings, customize game simulations, and analyze side-by-side matchups for more than a dozen sports.

With March Madness Selection Sunday fast approaching on March 16, fans can use the Versus Sports Simulator to make informed decisions when filling out their NCAA Tournament brackets. The platform’s advanced data models provide valuable insights for identifying potential upsets, sleeper teams, and tournament favorites.

“As someone who’s personally used the Versus Sports Simulator to win my own tournament pool four of the past five years, I can confidently say — it works!” said Pugh. “I wouldn’t suggest blindly following every prediction when filling out your bracket, though. I use the tool to help me identify matchups that deserve a closer look, and then I do my homework only on those matchups. I find that it speeds up the process tremendously and helps me identify the most probable Final Four teams. And Versus Sports Simulator provides a unique blend of statistical team data that I find to be much more insightful than focusing only on player stats.”

In addition to helping fans with their brackets, Versus Sports Simulator is also available to provide daily or weekly Top 25 rankings for Men’s D1/D2/D3 and Women’s D1 basketball to interested media outlets. For journalists or publications looking to feature weekly rankings in their coverage, please reach out directly.

Explore the new rankings here:

NCAA D1 Women’s College Basketball RankingsNCAA D2 Men’s College Basketball RankingsNCAA D3 Men’s College Basketball Rankings

For additional information or media inquiries, visit VersusSportsSimulator.com or contact Steve Pugh directly.

Media Contact

Steve Pugh, Versus Sports Simulator, 1 8045370281, steve@versussportssimulator.com, https://www.versussportssimulator.com/

View original content:https://www.prweb.com/releases/versus-sports-simulator-expands-coverage-to-include-womens-d1-college-basketball-and-mens-d2d3-college-basketball-302402167.html

SOURCE Versus Sports Simulator

Continue Reading

Technology

Adapting to AI Regulations: Risk-Based Compliance Strategy From Info-Tech Research Group

Published

on

By

Info-Tech Research Group unveils a comprehensive four-step blueprint to help IT leaders navigate the growing complexity of AI compliance. The risk-based approach outlined in the resource provides IT leaders with crucial insights to mitigate legal exposure, stay ahead of tightening global regulations, and address emerging ethical challenges in the AI landscape.

TORONTO, March 14, 2025 /PRNewswire/ – Artificial intelligence is evolving at an unprecedented pace, bringing both opportunities and regulatory challenges for organizations worldwide. Recent developments, such as Spain’s new law imposing fines on unlabeled AI-generated content and legal action against Meta in France over AI training data, highlight the growing scrutiny surrounding AI compliance. Global research and advisory firm Info-Tech Research Group has a newly published resource, Develop an AI Compliance Strategy that provides organizations with a structured and risk-based approach to navigating these challenges. By following the framework outlined in this research, IT leaders can balance innovation with accountability, strengthen customer trust, and ensure long-term success.

“AI technologies are rapidly advancing, and complex regulations are emerging constantly to keep pace. Different jurisdictions have their own AI regulations, leading to a patchwork of rules that organizations must navigate,” says Safayat Moahamad, research director at Info-Tech Research Group. “While there is a growing need for AI solutions to address various business challenges, organizations must be cognizant of the obligations they may be subject to.”

Info-Tech’s insights in its Develop an AI Compliance Strategy resource explores the challenges and opportunities organizations face with the rapid rise of AI. The firm’s researchers highlight that AI applications rely on extensive data processing, making data privacy and security key concerns. As organizations work to address these challenges, establishing a clear and effective AI compliance strategy becomes essential. This process requires careful planning and prioritization to ensure compliance efforts are both comprehensive and manageable. Info-Tech advises that adopting a risk-based approach aligned with global standards allows organizations to focus on critical activities and navigate regulatory requirements with confidence.

“Business leaders have a responsibility to understand which local, national, and industry-specific regulations and standards for AI apply to their organization,” explains Moahamad. “They must identify AI systems, applications, and related vendors used within the organization.”

Info-Tech has outlined a four-step approach to help organizations proactively anticipate and address AI regulatory requirements. As AI continues to present significant opportunities for innovation and efficiency, the firm explains in its blueprint that it is crucial for organizations to balance these advantages with the challenges of compliance, transparency, and trust.

The four-step approach for IT leaders navigating AI regulatory requirements includes:

Identify AI systems and applications: Gain visibility by identifying current and planned AI solutions and develop a comprehensive portfolio of AI investments.Define controls necessary to govern the AI system: Establish controls that align with regulatory obligations and best practices to assess compliance with a responsible AI framework.Implement tasks and actions to mitigate risks: Prioritize initiatives to create a roadmap for achieving compliance, ensuring stakeholders are aligned on implementing necessary controls within established timelines.Monitor the effectiveness of the compliance program: Define metrics to track progress, periodically reviewing metrics and communicating updates to stakeholders.

By following the structured approach detailed in the blueprint, organizations can streamline the complex process of managing AI compliance. Info-Tech’s data-backed research advocates for a risk-based strategy aligned with international standards, enabling organizations to focus on critical tasks while addressing data privacy, security concerns, and regulatory obligations. This comprehensive strategy fosters responsible AI development to help IT leaders minimize legal and reputational risks and drive long-term success.

For exclusive and timely commentary from Safayat Moahamad, an expert in global privacy and cybersecurity trends, and access to the complete Develop an AI Compliance Strategy blueprint, please contact pr@infotech.com.

About Info-Tech Research Group
Info-Tech Research Group is one of the world’s leading research and advisory firms, proudly serving over 30,000 IT and HR professionals. The company produces unbiased, highly relevant research and provides advisory services to help leaders make strategic, timely, and well-informed decisions. For nearly 30 years, Info-Tech has partnered closely with teams to provide them with everything they need, from actionable tools to analyst guidance, ensuring they deliver measurable results for their organizations.

To learn more about Info-Tech’s divisions, visit McLean & Company for HR research and advisory services and SoftwareReviews for software buying insights.

Media professionals can register for unrestricted access to research across IT, HR, and software and hundreds of industry analysts through the firm’s Media Insiders program. To gain access, contact pr@infotech.com.

For information about Info-Tech Research Group or to access the latest research, visit infotech.com and connect via LinkedIn and X.

View original content to download multimedia:https://www.prnewswire.com/news-releases/adapting-to-ai-regulations-risk-based-compliance-strategy-from-info-tech-research-group-302402180.html

SOURCE Info-Tech Research Group

Continue Reading

Trending